Inflammation in white matter: Clinical and pathophysiological aspects

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 12, Issue 2, 2006, Pages 141-146

  Pleasure, David ^a,d   Soulika, Athena ^a   Singh, Sunit K ^a   Gallo, Vittorio ^b   Bannerman, Peter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Section of Allergy and Immunology   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

Author keywords

Axonal disruption; Inflammation; Multiple sclerosis; Oligodendroglia; Periventricular leukomalacia

Indexed keywords

ANTIGEN; MYELIN;

ADULTHOOD; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; CEREBRAL PALSY; CLINICAL STUDY; ENCEPHALITIS; ENCEPHALOMALACIA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; HYPOXIA; IMMUNE MEDIATED INJURY; IMMUNE RESPONSE; INNATE IMMUNITY; ISCHEMIA; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WHITE MATTER; WHITE MATTER DISORDER;

EID: 33745714340     PISSN: 10804013     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/mrdd.20100     Document Type: Review

References (89)

1. Anderson DW, Ellenberg JH, Leventhal CM, et al. 1992. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31:333-336.
2. Back SA, Luo NL, Borenstein NS, et al. 2001. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 21:1302-1312.
3. Back SA, Luo NL, Mallinson RA, et al. 2005. Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol 58:108-120.
4. Balashov KE, Rottman JB, Weiner HL, Hancock WW. 1999. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 96:6873-6878.
5. Banker BQ, Larroche JC. 1962. Periventricular leukomalacia of infancy. A form of neonatal anoxic encephalopathy. Arch Neurol 7:386-410.
6. Bannerman PG, Hahn A, Ramirez S, et al. 2005. Motor neuron pathology in experimental autoimmune encephalomyelitis: Studies in THY1-YFP transgenic mice. Brain 128:1877-1886.
7. Barnett MH, Pnneas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly formed lesion. Ann Neurol 55:458-468.
8. Bashir K, Whitaker JN. 1999. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 53:765-771.
9. Bass WT, Schultz SJ, Burke BL, et al. 2002. Indices of hemodynamic and respiratory functions in premature infants at risk for the development of cerebral white matter injury. J Perinatol 22:64-71.
10. Bell MJ, Hallenbeck JM, Gallo V. 2004. Determining the fetal inflammatory response in an experimental model of intrauterine inflammation in rats. Pediatr Res 56:541-546.
11. Benedict RHB, Zivadinov R, Carone DA, et al. 2005. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol 26:1824-1831.
12. Berger T, Rubner P, Schautzer F, et al. 2003. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349:139-145.
13. Brazel CY, Rosti RT III, Boyce S, et al. 2004. Perinatal hypoxia/ischemia damages and depletes progenitors from the mouse subventricular zone. Dev Neurosci 26:266-274.
14. Cepok S, Zhou D, Srivastava R, et al. 2005. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115:1352-1360.
15. Charcot JM. 1877. Lectures on the Diseases of the Nervous System, delivered at La Salpetriere (translated by Sigerson G). London: New Sydenham Society.
16. Corcione A, Casazza S, Ferretti E, et al. 2004. Recapitulation of B cell differentiation in the CNS of patients with multiple sclerosis. Proc Natl Acad Sci USA 101:11064-11069.
17. Dale RC, de Sousa C, Chong WK, et al. 2000. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123:2407-2422.
18. Dammann O, Hagberg H, Leviton A. 2001. Is periventricular leukomalacia an axonopathy as well as an oligopathy? Pediatr Res 49:453-457.
19. Darabi K, Karulin AY, Boehm BO, et al. 2004. The third signal in T cell-mediated autoimmune disease? J Inimunol 173:92-99.
20. De Stefano N, Matthews PM, Filippi M, et al. 2003. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 60:1157-1162.
21. De Vries LS, van Haastert I-LC, Rademaker KJ, et al. 2004. Ultrasound abnormalities preceding cerebral palsy in high-risk preterm infants. J Pediatr 144:815-820.
22. Du Pasquier RA, Autissier P, Zheng.Y, et al. 2005. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: Rationale for immune-based therapeutic strategies. AIDS 19:2069-2076.
23. Ebert S, Gerber J, Bader S, et al. 2005. Dose-dependent activation of microglial cells by toll-like receptor agonists alone and in combination. J Neuroimmunol 159:87-96.
24. Engelhardt B, Ransohoff RM. 2005. The ins and outs of T-lymphocyte trafficking to the CNS: Anatomical sites and molecular mechanisms. Trends Immunol 26:485-495.
25. Feng G, Mellor RH, Bernstein M, et al. 2000. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41-51.
26. Follett PL, Deng W, Dai W, et al. 2004. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: A protective role for topiramate. J Neurosci 24:4412-4420.
27. Follett PL, Rosenberg PA, Volpe JJ, Jensen FC. 2000. NBQX attenuates exciitotoxic injury in developing white matter. J Neurosci 20:9235-9241.
28. Frohman EM, Filippi M, Stuve O, et al. 2005. Characterizing the mechanisms of progression in multiple sclerosis. Evidence and new hypotheses for future directions. Arch Neurol 62:1345-1356.
29. Galli KK, Zimmerman RA, Jarvik GP, et al. 2004. Periventricular leukomalacia is common after neonatal cardiac surgery. J Thorac Cardiovasc Surg 127:692-704.
30. Hafler DA. 1999. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest 104:527-529.
31. Hagborg H, Peebles D, Mallard C. 2002. Models of white matter injury: Comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Ment Retard Dev Disabil Res Rev 8:30-38.
32. Haynes RL, Folkerth RD, Keefe RJ, et al. 2003. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 62:441-450.
33. Hemachudha T, Griffin DE, Giffels JJ, et al. 1987. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 316:369-374.
34. Hollsberg P, Kusk M, Bech E, et al. 2005. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: Associations with disease activity. Acta Neurol Scand 112:395-402.
35. Itoh T, Beesley J, Itoh A, et al. 2002. AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem 81:390-402.
36. Jack C, Ruffini F, Bar-Or A, Antel JP. 2005. Microglia and multiple sclerosis. J Neurosci Res 81:363-373.
37. Kadhim H, Tabarki B, De Prez C, et al. 2002. Interleukin-2 in the pathogenesis of perinatal white matter damage. Neurology 58:1125-1128.
38. Kanwar JR, Kanwar RK, Krissansen GW. 2004. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain 127:1313-1331.
39. Keegan M, Konig F, McClelland R, et al. 2005. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579-582.
40. Kleinschmidt-DeMasters BK, Tyler KL 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and Interferon β-1a for multiple sclerosis. N Engl J Med 353:369-374.
41. Kubota T, Okumura A, Hayakawa F, et al. 2002. Combination of neonatal electroencephalography and ultrasonography: Sensitive means of early diagnosis of periventricular leukomalacia. Brain Dev 24:698-702.
42. Lampasona V, Franciotta D, Furlan R, et al. 2004. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 62:2092-2094.
43. Larroque B, Marret S, Ancel P-Y, et al. 2003. White matter damage and intraventricular hemorrhage in very preterm infants: The EPIPAGE study. Disabil Rehabil 143:477-483.
44. Lassmann H. 2003. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 206:187-201.
45. Law M, Saindane AM, Ge Y, et al. 2004. Microvascular abnormality in relapsing-remitting multiple sclerosis: Perfusion MR imaging findings in normal-appearing white matter. Radiology 231:645-652.
46. Lehnardt S, Lachance C, Patrizi S, et al. 2002. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 22:2478-2486.
47. Leviton A, Gilles FH. 1984. Acquired perinatal leukoencephalopathy. Ann Neurol 16:1-8.
48. Lincoln MR, Montpetit A, Cader MZ, et al. 2005. A predominant role for the HLA class II region in the associatioin of the MHC region with multiple sclerosis. Nat Genet 37:1108-1112.
49. Lucchinetti C, Bruck W, Parisi J, et al. 2000. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707-717,
50. Marin-Padilla M. 1997. Developmental neuropathology and impact of perinatal brain damage. II. White matter lesions of the neocortex. J Neuropathol Exp Neurol 56:219-235.
51. McMahon EJ, Bailey SL, Castenada CV, et al. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11:335-339.
52. Menge T, Hemmer B, Nessler S, et al. 2005. Acute disseminated encephalomyelitis: An update. Arch Neurol 62:1673-1680.
53. Miller SP, Ferriero DM, Leonard C, et al. 2005. Early brain injury in premature newborns detected with magnetic resonance imaging is associated with adverse early neurodevelopmental outcome. Disabil Rehabil 147:609-616.
54. Muhle R, Trentacoste SV, Rapin I. 2004. The genetics of autism. Pediatrics 113:e472-e486.
55. + cells. J Immunol 175:959-966.
56. O'Connor KC, Appel H, Bregoli L, et al. 2005. Antibodies from inflamed CNS tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 175:1974-1982.
57. Oksenberg JR, Panzara MA, Begovich AB, et al. 1993. Selection for T-cell receptor V β-D β-J β gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362:68-70.
58. Olson JK, Miller SD. 2004. Microglia initiate CNS innate and adaptive immune responses through multiple TLRs. J Immunol 173:3916-3924.
59. Opsahl ML, Kennedy PG. 2005. Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 128:516-527.
60. Paintlia MK, Paintlia AS, Barbosa E, et al. 2004. N-Acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J Neurosci Res 78:347-361.
61. Papadopoulos D, Pham-Dinh D, Reynolds R. 2006. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol 197:373-385.
62. Peeters-Scholte C, Koster J, Veldhuis W, et al. 2002. Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal hypoxia-ischemia. Stroke 33:2304-2310.
63. Perron H, Lazarini F, Ruprecht K, et al. 2005. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: Physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol 22:23-33.
64. Pittock SJ, McClelland RL, Achenbach SJ, et al. 2005. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatr 76:1693-1697.
65. Polman CH, Reingold SC, Edan G, et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846.
66. Reich D, Patterson N, De Jager PL, et al. 2005. A whole-genome admixture scan finds a candidate locus for mutiple sclerosis susceptibility. Nat Genet 37:1113-1118.
67. Sastre-Garriga J, Ingle GT, Chard DT, et al. 2005. Grey and white matter volume changes in early primary progressive multiple sclerosis: A longitudinal study. Brain 128:1454-1460.
68. Sawcer S, Ban M, Maranian M, et al. 2005. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 77:454-467.
69. Serafini B, Rosicarelli B, Magliozzi R, et al. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14164-14174.
70. Sherwin C, Fern R. 2005. Acute lipopolysaccharide-mediated injury in neonatal white matter glia: Role of TNF-α, IL-1β, and calcium. J Immunol 175:155-161.
71. Skoff RP, Bessert DA, Barks JDE, et al. 2001. Hypoxic-ischemic injury results in acute disruption of myelin gene expression and death of oligodendroglial precursors in neonatal mice. Int J Dev Neurosci 19:197-208.
72. Sospedra M, Martin R. 2005. Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747.
73. Steinman L, Zamvil SS. 2005. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol 26:565-571.
74. Suzuki M, Okumura A, Watanabe K, et al. 2003. The predictive value of electroencephalogram during early infancy for later development of West syndrome in infants with cystic periventricular leukomalacia. Epilepsia 44:443-446.
75. Trapp BD, Peterson J, Ransohoff RM, et al. 1998. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285.
76. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. 1997. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 99:1682-1690.
77. Tuohy VK, Yu M, Yin L, et al. 1999. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 189:1033-1042.
78. van Gelder-Hasker MR, van Wezel-Meijler G, de Groot L, et al. 2003. Peri- and intraventricular cerebral sonography in second- and third-trimester high-risk fetuses: A comparison with neonatal ultrasound and relation to neurological development. Ultrasound Obstet Gynecol 22:110-120.
79. Vannucci RC, Vannucci SJ. 2005. Perinatal hypoxic-ischemic brain damage: Evolution of an animal model. Dev Neurosci 27:81-86.
80. Verma U, Tejani N, Klein S, et al. 1997. Obstetric antecedents of intraventricular hemorrhage and periventricular leukomalacia in the low-birth-weight neonate. Am J Obstet Gynecol 186:275-281.
81. Virchow R. 1868. Uber interstitielle Encephalitis. Virchow Arch Pathol Anat 44:472-476.
82. Volpe JJ. 2001. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res 50:553-562.
83. Volpe JJ. 2003. Cerebral white matter injury of the premature infant-more common than you think. Pediatrics 112:176-180.
84. Wei X, Zhao L, Ma Z, et al. 2004. Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. Brain 127:2629-2635.
85. Weinshenker BG, Bass B, Rice GP, et al. 1989. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 112:133-146.
86. Wharton KN, Pinar H, Stonestreet BS, et al. 2004. Severe umbilical cord inflammation-A predictor of periventricular leukomalacia in very low birth weight intants. Early Hum Dev 77:77-87.
87. Willer CJ, Dyment DA, Risch NJ, et al. 2003. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 100:12877-12882.
88. Wu YW, Colford JM Jr. 2000. Chorioamnionitis as a risk factor for cerebral palsy: A metaanalysis. JAMA 284:1417-1424.
89. Yuan X, Chittajallu R, Belachew S, et al. 2002. Expression of the green fluorescent protein in the oligodendrocyte lineage: A transgenic mouse for developmental and physiological studies. J Neurosci Res 70:529-545.